Clinical Outcomes | Healix

Optimal Vancomycin Model Selection for Obese Patients Receiving Outpatient Parenteral Antimicrobial Therapy (OPAT)

Oct 18, 2024 | Clinical Outcomes

Presented at IDWeek 2024 Authors: Kimberly A. Couch, PharmD, MA, FIDSA, FASHP Quyen Luu, MD Richard C. Prokesch, MD, FACP, FIDSA John S. Adams, MD, FIDSA, FSHEA Joseph F. John, Jr., MD, FACP, FIDSA Lucinda J. Van Anglen, BS, PharmD, FIDSA View...

Reductions in LDL-C within the First Year of Treatment with Inclisiran: Results from a Multicenter Real World Cohort

Apr 7, 2024 | Clinical Outcomes

Presented at ACC 2024 Authors: Christie M. Ballantyne Tyler Varisco Timothy Graham Bruce J. Iteld Harvey Serota Sean McElligott Xiaoli Niu Kelly Hanna Lucinda Van Anglen View Poster

Immune Globulin Subcutaneous 16.5% in the Treatment of Primary Immunodeficiency: A Two-Year Multicenter Analysis

Feb 24, 2024 | Clinical Outcomes

Presented at AAAAI 2024 Authors: Richard F. Herrscher, MD, FACAAI Jeffrey W. Langford, MD, AE-C Precious A. Anyanwu, PharmD, PhD Lucinda J. Van Anglen, PharmD View Poster

Real-World Outcomes with Subcutaneous Immunoglobulin 16.5% in the Treatment of Primary Immunodeficiency

Oct 8, 2023 | Clinical Outcomes

Presented at IgNS 2023 Authors: Lucinda J. Van Anglen, PharmD Jeffrey W. Langford, MD, AE-C Richard F. Herrscher, MD, FACAAI Precious A. Anyanwu, PharmD, PhD View Poster

Real-World Outcomes After Switching to Immune Globulin Subcutaneous 16.5% In Patients with Primary Humoral Immunodeficiency: A 3-Year Study

Feb 25, 2023 | Clinical Outcomes

Presented at AAAAI 2023 Authors: Jeffrey W. Langford, MD, AE-C Richard F. Herrscher, MD, FACAAI Dawn N. Kim-Romo, PharmD, PhD, MS Lucinda J. Van Anglen, PharmD View Poster

Treatment With Intravenous Immune Globulin 10% In A Real-World Outpatient Setting

Feb 25, 2023 | Clinical Outcomes

Presented at AAAAI 2023 Authors: Richard F. Herrscher, MD, FACAAI Kevin Rosenbach, MD Quyen Luu, MD Dawn N. Kim-Romo, PharmD, PhD, MS Lucinda J. Van Anglen, PharmD View Poster

Optimal Vancomycin Model Selection for Obese Patients Receiving Outpatient Parenteral Antimicrobial Therapy (OPAT)

Reductions in LDL-C within the First Year of Treatment with Inclisiran: Results from a Multicenter Real World Cohort

Immune Globulin Subcutaneous 16.5% in the Treatment of Primary Immunodeficiency: A Two-Year Multicenter Analysis

Real-World Outcomes with Subcutaneous Immunoglobulin 16.5% in the Treatment of Primary Immunodeficiency

Real-World Outcomes After Switching to Immune Globulin Subcutaneous 16.5% In Patients with Primary Humoral Immunodeficiency: A 3-Year Study

Treatment With Intravenous Immune Globulin 10% In A Real-World Outpatient Setting

Recent Posts

Recent Comments

Archives

Categories

Meta